Abstract:Abstract Acute myeloid leukemia (AML) is often accompanied with the aberrant expression of transcription factors. In t(8;21) AML, the AML1-ETO fusion protein executes its critical role in leukemogenesis through the interference with hematopoietic transcription factors (TFs) including AML1, C/EBPα, PU.1 and c-Myb. These transcription factors cooperate to modulate hematopoiesis by regulating their differentiation-related target genes. In our previous work, we have identified that AML1-ETO suppresses the AML1-dependent transactivation of the gene encoding the neutrophil granule protease, cathepsin G (CTSG). However, the detailed mechanisms of AML1-ETO mediated transrepression, especially coordinated regulation of hematopoietic transcription factors, have not been characterized yet. To investigate the regulatory pattern of CTSG by hematopoietic specific transcription factors, we constructed a luciferase reporter containing the CTSG promoter and co-transfect it with AML1, c-Myb, C/EBPα or PU.1 to 293T cells. The results of luciferase assays showed that these TFs individually activated the CTSG promoter, and synergistic transactivation occurred between AML1 and c-Myb, C/EBPα and PU.1, and PU.1 and c-Myb on the CTSG promoter. Furthermore, AML1/ETO effectively suppressed the transcription factor-dependent transactivation and synergistic transactivation of the CTSG promoter. Chromatin immunoprecipitation assays further demonstrated that AML1-ETO coexisted with these TFs on the CTSG promoter in AML1/ETO-positive Kasumi-1 cell line, indicating AML1-ETO was tethered to the chromatin bound by these TFs. The data suggested that AML1-ETO might act as a negative regulator by interfering the normal function of hematopoietic TFs instead of competing for their binding. In addition, to reveal the underlying mechanism of AML1/ETO-mediated transcription repression at the epigenetic level, we examined the epigenetic status of the CTSG promoter in AML1-ETO negative and positive cells, and found the level of histone H3 Lys9 acetylation on the CTSG promoter was obviously lower in AML1-ETO positive cells than that in AML1-ETO negative cells. The data suggested that AML1-ETO might repress the gene transcription by changing the H3 acetylation status of its target gene. Collectively, our findings demonstrate that AML1-ETO represses the transactivation of the CTSG promoter mediated by multiple hematopoietic transcription factors through a decrease of H3 acetylation. Disclosures: No relevant conflicts of interest to declare.

Downstream Pathway of AML1-ETO Targeted ARHGEF12 Might Be Targetable for Rock Inhibitor to Improve Therapy Outcome

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients

Arhgef12 Regulates Erythropoiesis And Is Involved In Erythroid Regeneration After Chemotherapy In Acute Lymphoblastic Leukemia Patients

Clinical Implication and Potential Function of ARHGEF6 in Acute Myeloid Leukemia: an in Vitro Study.

The role of Rho guanine nucleotide exchange factor 12 (ARHGEF12) in leukemia cell growth

Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia

AML1-ETO inhibits acute myeloid leukemia immune escape by CD48

AML1-ETO Represses Multiple Transcription Factor Induced CTSG Activation by Reducing H3 Acetylation

High expression of ARHGEF5 predicts unfavorable prognosis in acute myeloid leukemia

Comparative Proteomic Analysis of Human Leukemic Cells with and Without Inducible Expression of Leukemogenic AML1-ETO Protein.

Targeting ARHGEF12 Promotes Neuroblastoma Differentiation, MYCN Degradation, and Reduces Tumorigenicity.

Aberrant Transcriptional Regulation of the MLL Fusion Partner EEN Gene by AML1-ETO and Its Implication in Leukemogenesis.

Analysis of clinical outcome of childhood acute myeloid leukemia with AML_1-ETO

The Leukemia-Associated Rho Guanine Nucleotide Exchange Factor (LARG) /ARHGEF12 is Important for Erythroid Differentiation

Epigenetic silencing of Bcl-2, CEBPA and p14ARF by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line

An Integrative Analysis-Based Method for Predicting Target Genes of AML1-ETO Fusion Protein

Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells

ZFP36L2, a Novel AML1 Target Gene, Induces AML Cells Apoptosis and Inhibits Cell Proliferation

AML1‐ETO Interacts with Sp1 and Antagonizes Sp1 Transactivity Through RUNT Domain